Article
Biochemistry & Molecular Biology
Anja Saalbach, Ulf Anderegg, Ralph Wendt, Joachim Beige, Anette Bachmann, Nora Kloeting, Matthias Blueher, Ming-Zhi Zhang, Raymond C. Harris, Michael Stumvoll, Anke Toenjes, Thomas Ebert
Summary: Kidney fibrosis, a major factor in chronic kidney disease (CKD), leads to irreversible organ function loss. This study investigated the association of the soluble form of Thymocyte differentiation antigen-1 (sThy-1) with clinical parameters in CKD patients receiving hemodialysis. The study also examined Thy-1 tissue expression in a mouse model of diabetic CKD. The results showed that sThy-1 levels increased with worsening renal function, regardless of the presence of diabetes. Serum creatinine was found to be a major predictor of sThy-1 levels. Additionally, sThy-1 was found to be an independent predictor of markers of renal function. The study suggests that Thy-1 may have a role in controlling kidney fibrosis and could potentially be used as a renal antifibrotic factor.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Carl-Philipp Hackstein, Jasper Spitzer, Konstantinos Symeonidis, Helena Horvatic, Tanja Bedke, Babett Steglich, Sabine Klein, Lisa M. Assmus, Alexandru Odainic, Jennifer Szlapa, Nina Kessler, Marc Beyer, Ricarda Schmithausen, Eicke Latz, Richard A. Flavell, Natalio Garbi, Christian Kurts, Beate M. Kuemmerer, Jonel Trebicka, Axel Roers, Samuel Huber, Susanne V. Schmidt, Percy A. Knolle, Zeinab Abdullah
Summary: Patients with chronic liver disease (CLD) are more susceptible to viral infections and have a reduced response to vaccination. The study found that liver injury leads to microbial translocation and increased levels of type I interferon (IFN-I), which induces excessive IL-10 production during viral infection, leading to dysfunctional T-cell immunity. Blocking IFN-I and IL-10 signaling can restore antiviral immunity in patients with liver injury.
JOURNAL OF HEPATOLOGY
(2023)
Article
Medicine, General & Internal
Jana Enderes, Jessica Teschke, Steffen Manekeller, Tim O. Vilz, Joerg C. Kalff, Tim R. Glowka
Summary: According to the study, there was no significant difference in DGE impact after PD between patients with LC and LF and those without liver pathologies. However, patients with LC and LF may have higher ASA score, receive more intraoperative erythrocyte transfusions, stay longer in the ICU, and have more intraabdominal abscess formation.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Dong Ji, Yan Chen, Qinghua Shang, Huabao Liu, Lin Tan, Jing Wang, Yongping Chen, Qin Li, Qinghua Long, Laicheng Song, Li Jiang, Guangming Xiao, Zujiang Yu, Liang Chen, Xiaoyu Hu, Xiaodong Wang, Da Chen, Zhiqin Li, Zheng Dong, Guofeng Chen, Yongping Yang
Summary: The study aimed to assess the association between changes in liver stiffness measurement (LSM) and histological outcomes in chronic hepatitis B patients receiving entecavir-based therapy. LSM decrease of ≥30% was associated with regression of fibrosis, significant histological response, and alanine aminotransferase normalization, with a new on-treatment LSM cutoff value established for indicating significant histological response.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Immunology
Angus Hann, Ye H. Oo, M. Thamara P. R. Perera
Summary: The liver possesses unique immunological characteristics but is susceptible to immune mediated injury. Regulatory T cells play a crucial role in preventing tissue damage, and therapies aiming to increase their function have shown efficacy in autoimmune diseases and organ transplantations. Research on the hepatic microenvironment and the role of Tregs in liver diseases is crucial for maintaining immunological balance.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Dmitrii Shek, Dishen Chen, Scott A. Read, Golo Ahlenstiel
Summary: Liver cancer, predicted to be the third most lethal cancer worldwide by 2030, is primarily caused by obesity, chronic alcohol abuse or viral hepatitis, with alcohol and high fat diet promoting intestinal permeability. Understanding the mechanisms by which liver cancers initiate and progress is crucial, and organoid culture offers advantages for studying the role of the gut-liver axis in cancer initiation and progression.
Review
Cell & Tissue Engineering
Farnaz Sani, Mahsa Sani, Zahra Moayedfard, Maryam Darayee, Lobat Tayebi, Negar Azarpira
Summary: Liver damage caused by toxicity can lead to severe conditions such as acute liver failure, fibrogenesis, and cirrhosis, with liver cirrhosis being the leading cause of liver-related deaths globally. Transplantation of gene-engineered stem cells is a potential therapeutic approach to improve liver function. Genetic engineering enhances the regenerative potential of stem cells by releasing growth factors and cytokines. Further research is recommended to develop safe gene modification methods and ensure long-term patient follow-up to increase the effectiveness and reliability of these therapeutic strategies.
STEM CELL RESEARCH & THERAPY
(2023)
Article
Gastroenterology & Hepatology
Tianlu Chen, Kejun Zhou, Tao Sun, Chao Sang, Wei Jia, Guoxiang Xie
Summary: The study revealed the association of conjugated bile acids structure changes with chronic liver disease progression, and established three diagnostic models based on the ratios of 15 bile acids for distinguishing early and advanced stages of the disease. The models showed good performance in test sets.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Pharmacology & Pharmacy
Qiuyu Cai, Can Gan, Chengwei Tang, Hao Wu, Jinhang Gao
Summary: Histone modifications play a crucial role in the pathogenesis of chronic liver disease and provide a potential target for therapeutic interventions. Pharmacological modulation of histone modifications may offer a promising approach to reverse CLD and prevent progression to liver cirrhosis and malignancy.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Huapeng Lin, Grace Lai-Hung Wong, Xinrong Zhang, Terry Cheuk-Fung Yip, Ken Liu, Yee Kit Tse, Vicki Wing-Ki Hui, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong
Summary: This study aimed to determine the association between blood urea level and incident cirrhosis, hepatic decompensation, and hepatocellular carcinoma in patients with chronic liver disease. The results showed a U-shaped relationship between blood urea level and hepatic decompensation and cirrhosis, with both low and high urea levels associated with higher risks.
CLINICAL AND MOLECULAR HEPATOLOGY
(2022)
Article
Medicine, General & Internal
Pei-Yuan Su, Yang-Yuan Chen, Jun-Hung Lai, Hung-Ming Chen, Chih-Ta Yao, I-Ling Liu, Ya-Huei Zeng, Siou-Ping Huang, Yu-Chun Hsu, Shun-Sheng Wu, Fu-Yuan Siao, Hsu-Heng Yen
Summary: This study evaluated the safety and efficacy of glecaprevir/pibrentasvir in patients with compensated cirrhosis in a real-world setting. The treatment regimen was found to be highly effective and well tolerated among these patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Norihisa Nishimura, Davide De Battista, David R. McGivern, Ronald E. Engle, Ashley Tice, Rafaelle Fares-Gusmao, Juraj Kabat, Anna Pomerenke, Hanh Nguyen, Shinya Sato, Kevin W. Bock, Ian N. Moore, David E. Kleiner, Fausto Zamboni, Harvey J. Alter, Sugantha Govindarajan, Patrizia Farci
Summary: This study found that CHI3L1 promotes liver fibrogenesis through a direct effect on HSCs, supporting a role for CHI3L1 in the increased susceptibility of aging livers to fibrosis progression.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Gastroenterology & Hepatology
Ludivine Legros, Edouard Bardou-Jacquet, Bruno Turlin, Sophie Michalak, Stephanie Hamonic, Antonia Le Gruyer, Karim Aziz, Cynthia Lemoine, Nicole Bouvard, Jean-Jacques Chavagnat, Christine Silvain, Jacqueline Kerjean, Gerard Le Dreau, Natacha Lacave-Oberti, Frederic Oberti, Caroline Le Lan, Dominique Guyader, Romain Moirand
Summary: Liver stiffness measurement performed during the first 2 months after alcohol cessation is an excellent method for excluding alcohol-related compensated advanced chronic liver disease (cACLD).
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Paul N. Brennan, Ahmed M. Elsharkawy, Timothy J. Kendall, Rohit Loomba, Derek A. Mann, Jonathan A. Fallowfield
Summary: Tackling fibrosis in NASH is crucial in improving patient outcomes, but approved antifibrotic therapy remains elusive. Increased understanding of NASH pathogenesis and emerging technologies provide promise for better drug development. Precision medicine and combination therapy strategies may improve future clinical success.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Zhen Liu, Xinyan Zhang, Yanrong Wang, Yifan Tai, Xiaolin Yao, Adam C. Midgley
Summary: This review summarizes emergent antifibrotic peptides and their utilization for targeted prevention of myofibroblasts, highlighting recent studies on peptide inhibitors of upstream pathogenic processes driving the formation of profibrotic cell phenotypes. Peptides from non-mammalian origins that show promise as antifibrotic therapeutics are also briefly discussed. Future perspectives of peptide design and development in targeting myofibroblasts to mitigate fibrosis are also addressed.
Article
Hematology
Antonio Petrarca, Luigi Rigacci, Patrizio Caini, Stefano Colagrande, Paolo Romagnoli, Francesco Vizzutti, Umberto Arena, Carlo Giannini, Monica Monti, Paolo Montalto, Marco Matucci-Cerinic, Alberto Bosi, Giacomo Laffi, Anna Linda Zignego
Article
Medicine, Research & Experimental
Sara Galastri, Elena Zamara, Stefano Milani, Erica Novo, Angela Provenzano, Wanda Delogu, Francesco Vizzutti, Salvatore Sutti, Irene Locatelli, Nadia Navari, Elisa Vivoli, Alessandra Caligiuri, Massimo Pinzani, Emanuele Albano, Maurizio Parola, Fabio Marra
Article
Gastroenterology & Hepatology
Roberto Giulio Romanelli, Giacomo Laffi, Francesco Vizzutti, Riccarda Del Bene, Fabio Marra, Patrizio Caini, Cristina Tosti Guerra, Giorgio La Villa, Giuseppe Barletta
DIGESTIVE AND LIVER DISEASE
(2011)
Article
Medicine, General & Internal
Roberto Tarquini, Emanuela Masini, Giorgio La Villa, Gianluigi Mazzoccoli, Rosanna Mastroianni, Roberto Giulio Romanelli, Francesco Vizzutti, Umberto Arena, Ugo Santosuosso, Giacomo Laffi
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2012)
Article
Gastroenterology & Hepatology
Valerio Nobili, Julie Parkes, Gianfranco Bottazzo, Matilde Marcellini, Richard Cross, Daniel Newman, Francesco Vizzutti, Massimo Pinzani, William M. Rosenberg
Article
Gastroenterology & Hepatology
Annalisa Berzigotti, Susana Seijo, Umberto Arena, Juan G. Abraldes, Francesco Vizzutti, Juan Carlos Garcia-Pagan, Massimo Pinzani, Jaime Bosch
Article
Gastroenterology & Hepatology
Francesco Vizzutti, Umberto Arena, Fabio Marra, Massimo Pinzani
Article
Gastroenterology & Hepatology
F. Vizzutti, U. Arena, L. Rega, M. Zipoli, J. G. Abraldes, R. G. Romanelli, R. Tarquini, G. Laffi, M. Pinzani
Letter
Medicine, General & Internal
Aldo Airoldi, Claudio Zavaglia, Francesco Vizzutti, Marcello Vangeli, Giovambattista Pinzello
INTERNAL AND EMERGENCY MEDICINE
(2009)
Article
Gastroenterology & Hepatology
Marco Trappoliere, Alessandra Caligiuri, Monika Schmid, Cristiana Bertolani, Paola Failli, Francesco Vizzutti, Erica Novo, Carlo di Manzano, Fabio Marra, Carmela Loguercio, Massimo Pinzani
JOURNAL OF HEPATOLOGY
(2009)
Article
Medicine, Research & Experimental
Francesco Vizzutti, Angela Provenzano, Sara Galastri, Stefano Milani, Wanda Delogu, Erica Novo, Alessandra Caligiuri, Elena Zamara, Umberto Arena, Giacomo Laffi, Maurizio Parola, Massimo Pinzani, Fabio Marra
LABORATORY INVESTIGATION
(2010)
Review
Anesthesiology
Francesco Vizzutti, Umberto Arena, Giacomo Laffi, Fabio Marra
TRENDS IN ANAESTHESIA AND CRITICAL CARE
(2013)
Article
Gastroenterology & Hepatology
Sara Messeri, Luca Messerini, Francesco Vizzutti, Giacomo Laffi, Fabio Marra
ANNALS OF HEPATOLOGY
(2012)
Review
Gastroenterology & Hepatology
Francesco Vizzutti, Umberto Arena, Valerio Nobili, Roberto Tarquini, Marco Trappoliere, Giacomo Laffi, Fabio Marra, Massimo Pinzani
ANNALS OF HEPATOLOGY
(2009)
Review
Oncology
A. Lunghi, P. Petreni, R. G. Romanelli, F. Vizzutti, F. Marra, R. Tarquini, G. Laffi
CASE REPORTS IN ONCOLOGY
(2014)
Article
Gastroenterology & Hepatology
Zhou Yuming, Tang Ruqi, Merrill Eric Gershwin, Ma Xiong
CLINICS IN LIVER DISEASE
(2024)
Article
Gastroenterology & Hepatology
Inbal Houri, Gideon M. Hirschfield
CLINICS IN LIVER DISEASE
(2024)
Article
Gastroenterology & Hepatology
Yasameen Muzahim, Ali Wakil, Mehak Bassi, Nikolaos Pyrsopoulos
CLINICS IN LIVER DISEASE
(2024)
Article
Gastroenterology & Hepatology
Brian H. Horwich, Douglas T. Dieterich
CLINICS IN LIVER DISEASE
(2024)
Article
Gastroenterology & Hepatology
Aparna Goel, Paul Kwo
Summary: The goal of autoimmune hepatitis treatment is achieving clinical and biochemical remission. Standard care involves induction treatment with corticosteroids and gradual tapering of steroids. Alternatives to standard therapy can be considered for patients with intolerance or inadequate response. Treatment withdrawal is achievable in less than 20% of patients after 2 years of sustained remission, and liver transplantation should be considered for patients with progressive disease or complications.
CLINICS IN LIVER DISEASE
(2024)
Article
Gastroenterology & Hepatology
Mariana Zapata, Hendrick Pagan-Torres, Marlyn J. Mayo
CLINICS IN LIVER DISEASE
(2024)
Article
Gastroenterology & Hepatology
Aalam Sohal, Sanya Kayani, Kris Kowdley
Summary: Primary sclerosing cholangitis (PSC) is an immune-mediated liver disease characterized by inflammation and fibrosis of bile ducts. It is commonly associated with inflammatory bowel disease, especially ulcerative colitis. The natural history of the disease varies among patients, but most will develop cirrhosis.
CLINICS IN LIVER DISEASE
(2024)